TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16411785

Group type: EXPERIMENTAL
Intervention: Music therapy interventions (including music and movement, active music listening, group chanting and singing, musical games, rhythmic training, music and sign language, and lyric analysis and rewrite activities)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Music therapy interventions
Number of subjects: 34
Study: 12817100

Group type: EXPERIMENTAL
Intervention: MMN recorded at 4 days after stroke onset
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MMN recorded at 3 months after stroke
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MMN recorded between 3 and 6 months after stroke
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Speech-comprehension tests during follow-up
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change in duration MMN amplitude
Number of subjects: 8
Study: 10974446

Group type: EXPERIMENTAL
Intervention: Severely anemic group (hemoglobin < 11.0 g/100 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-anemic group (hemoglobin ≥ 11.0 g/100 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Decrease in mean blood hemoglobin value by 1 g/100 mL
Number of subjects: 60
Study: 8625547

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1955231

Group type: EXPERIMENTAL
Intervention: Human natural leukocytic interferon (HNLI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recombinant interferon (rIFN) alpha 2c
Number of subjects: 72
Study: 6404979

Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg for first 10 days, then 300-200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg for the whole length of therapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spironolactone (both groups)
Number of subjects: 18
Study: 30989563

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study: 29058313

Group type: EXPERIMENTAL
Intervention: Early intervention programme
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27628221

Group type: EXPERIMENTAL
Intervention: Olmesartan added to combination of ACEI and BB in HFrEF patients
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Olmesartan added to BB alone in HFpEF patients
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Olmesartan not combined with BB in HFpEF patients
Number of subjects: 1147
Study: 24337725

Group type: EXPERIMENTAL
Intervention: Cognitive depression symptoms
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Depressive symptom severity
Number of subjects: 133
Study: 22927201

Group type: EXPERIMENTAL
Intervention: Oral betamethasone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20796307

Group type: EXPERIMENTAL
Intervention: Helium-oxygen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 19
Study: 17600286

Group type: EXPERIMENTAL
Intervention: peg‐IFN‐α2a 180 mcg s.c. once weekly + Ribavirin 1000‐1200 mg p.o. daily + Tα1 1.6 mg s.c. twice weekly for 24 weeks
Number of subjects: 638

Group type: COMPARATOR
Intervention: peg‐IFN‐α2a + Ribavirin
Number of subjects: 638
Study: 16227999

Group type: EXPERIMENTAL
Intervention: Genetic variation in SEPS1 (specifically the promoter variant ‐105G ‐‐> A)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Suppression of SEPS1 by short interfering RNA in macrophage cells
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Genotyping of ‐105G ‐‐> A in 419 Mexican American individuals
Number of subjects: 522
Study: 12137102

Group type: EXPERIMENTAL
Intervention: MCC (vapor compression microclimate cooling system)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PIC (personal ice cooling system)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TOTAL (total body cooling garment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SHIRT (hooded shirt‐only cooling garment)
Number of subjects: 8
Study: 9698948

Group type: EXPERIMENTAL
Intervention: 0.15, 0.30, or 0.45 mg/kg racemic ketamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 8
Study: 7869918

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1,200 mg/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: simvastatin (10 mg/d)
Number of subjects: 29
Study: 2229837

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with birch‐pollen extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 40
Study: 6289661

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose methotrexate
Number of subjects: 40
Study: 30802336

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control platelets
Number of subjects: 48
Study: 29208004

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study: 26209855

Group type: EXPERIMENTAL
Intervention: Neuraxial block
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 10010
Study: 25103125

Group type: EXPERIMENTAL
Intervention: FAST‐Feedback intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no FAST‐Feedback)
Number of subjects: 99
Study: 21909861

Group type: EXPERIMENTAL
Intervention: Hypocapnia group (RR adjusted to maintain PaCO(2) at 30 to 35 mmHg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normocapnia group (RR adjusted to maintain PaCO(2) at 35 to 45 mmHg)
Number of subjects: 100
Study: 19579193

Group type: EXPERIMENTAL
Intervention: High-frequency-powered electrothermal device (Precise™, Covidien)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional thyroid surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Device-supported thyroid surgery (Precise™ and Focus™)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Classic tie-and-knotting procedure
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 82
Study: 17557349

Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate (50mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 16487712

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 29
Study: 12909471

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 parts per million
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (historical subjects)
Number of subjects: 36
Study: 11083483

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Green tea polyphenol isolate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antioxidant beta-carotene
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antioxidant alpha-tocopherol
Number of subjects: 64
Study: 8767378

Group type: EXPERIMENTAL
Intervention: Transmediastinal dissection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transthoracic en bloc resection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study: 1997887

Group type: COMPARATOR
Intervention: Radiotherapy and chloroethylnitrosoureas (methyl‐CCNU, 100‐120 mg/m2, or ACNU 80‐100 mg/m2, every 6‐8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiotherapy and a combination of chloroethylnitrosoureas and tegafur (300 mg/m2, daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100
Study: 6438682

Group type: EXPERIMENTAL
Intervention: Experimental group (N = 20) underwent 4 days of tobacco deprivation
Number of subjects: 27
Study: 28722815

Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (2 mL Aqua)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg/mL)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 41
Study: 29228918

Group type: EXPERIMENTAL
Intervention: Nevirapine-based ART
Number of subjects: 284

Group type: COMPARATOR
Intervention: Efavirenz-based ART
Number of subjects: 284
Study: 25230071

Group type: EXPERIMENTAL
Intervention: Manual Wheelchair (MWC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 4-Wheeled Walker (WW)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Powered Wheelchair (PWC)
Number of subjects: 59
Study: 24899329

Group type: EXPERIMENTAL
Intervention: Kennedy Class III classification
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Gender and employment status comparison
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Upper arch vs lower arch
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Replacement of missing teeth
Number of subjects: 194
Study: 20962162

Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 46
Study: 18800990

Group type: EXPERIMENTAL
Intervention: PA counseling over the telephone and through mailed materials
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Change in PA from above threshold to below threshold
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Change in PA from below threshold to above threshold
Number of subjects: 357
Study: 15690666

Group type: EXPERIMENTAL
Intervention: Closed hemorrhoidectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy
Number of subjects: 80
Study: 12734746

Group type: COMPARATOR
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 6 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 2 years
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 4 years
Number of subjects: 37
Study: 10374214

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone continuously (n = 27; group T)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone (n = 25; group E-P)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No treatment (n = 24; group C)
Number of subjects: 76
Study: 8927658

Group type: EXPERIMENTAL
Intervention: ICI 204,636
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2071784

Group type: EXPERIMENTAL
Intervention: Standardized orchard grass-pollen extract or standardized mixed-pollen extract (specific immunotherapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6650449

Group type: EXPERIMENTAL
Intervention: Dietary intervention advising to change dietary habits (mainly reduce saturated fat)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (20 men)
Number of subjects: 42
Study: 30686102

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion surgery
Number of subjects: 68
Study: 31106551

Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 0.0625% ropivacaine
Number of subjects: 161

Group type: COMPARATOR
Intervention: no PCEA
Number of subjects: 161
Study: 29072019

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture combined with warm needling
Number of subjects: 86

Group type: COMPARATOR
Intervention: Warm needling (control group)
Number of subjects: 86
Study: 25471256

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (group-based sessions conducted twice a week for 9 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study: 23432476

Group type: EXPERIMENTAL
Intervention: Rituximab with plasmapheresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rituximab without plasmapheresis
Number of subjects: 20
Study: 22009807

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1µg/kg administered three minutes before anesthesia induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1µg/kg
Number of subjects: 60
Study: 19147455

Group type: EXPERIMENTAL
Intervention: Strict metabolic control by insulin (I-group; n = 21)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral glucose lowering agents (O-group; n = 18)
Number of subjects: 39
Study: 17760290

Group type: EXPERIMENTAL
Intervention: Reflective thermal inserts (RTI) and armor with supplementary irradiance (RA+I)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plain armor with supplementary irradiance (PA+I)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Reflective thermal inserts (RTI) and armor with no supplementary irradiance (RA-I)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Plain armor with no supplementary irradiance (PA-I)
Number of subjects: 4
Study: 15150623

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin (E) 80 mg/m² + Paclitaxel (T) 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Number of subjects: 234

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin + Paclitaxel (ET)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Paclitaxel (T)
Number of subjects: 234
Study: 11095453

Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg x day GH (n = 30)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg x day GH (n = 29)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 99
Study: 10178482

Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring strips prescribed
Number of subjects: 115

Group type: COMPARATOR
Intervention: No blood glucose monitoring strips prescribed
Number of subjects: 115
Study: 7902200

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment teaching module applied three hours per week for two to three months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment teaching module
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no education module)
Number of subjects: 20
Study: 3516921

Group type: EXPERIMENTAL
Intervention: Isotonic ioxaglate (Hexabrix‐20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Renografin‐76
Number of subjects: 0
Study: 30390355

Group type: EXPERIMENTAL
Intervention: Processed diets (PEL, EXTL, EXTH)
Number of subjects: 30
Study: 28343596

Group type: COMPARATOR
Intervention: Calcium hydroxide liner with RMGI restorations (Control group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: No calcium hydroxide liner with RMGI restorations (Test group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (with and without calcium hydroxide liner)
Number of subjects: 98
Study: 25794779

Group type: EXPERIMENTAL
Intervention: Amoxicillin (or clindamycin) given from one hour before operation until 3 days postoperatively
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo given at the same time as the antibiotic
Number of subjects: 207
Study: 23434109

Group type: EXPERIMENTAL
Intervention: Oral methionine (100 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 30
Study: 21242339

Group type: EXPERIMENTAL
Intervention: Solegg® and Solegg® Fine compressive stockings (15‐20 mmHg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual non‐compressive stockings (controls)
Number of subjects: 20
Study: 20396717

Group type: EXPERIMENTAL
Intervention: artrofoon
Number of subjects: 30

Group type: COMPARATOR
Intervention: nonsteroidal antiinflammatory preparations (NSAIDs)
Number of subjects: 30
Study: 17568028

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 245

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Anidulafungin (after removing data from the site enrolling the largest number of patients)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Fluconazole (after removing data from the site enrolling the largest number of patients)
Number of subjects: 245
Study: 15339439

Group type: EXPERIMENTAL
Intervention: Jieyu Huoxue Decoction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Depression control group
Number of subjects: 54
Study: 11434828

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 2884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d (secondary prevention cohort)
Number of subjects: 2884
Study: 10188716

Group type: EXPERIMENTAL
Intervention: N‐cadherin expression in normal and metaplastic OSE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E‐cadherin expression in OSE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P‐cadherin expression in OSE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal differentiation in (pre)‐neoplastic tissues
Number of subjects: 0
Study: 7778840

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Famciclovir 750 mg
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 2337520

Group type: EXPERIMENTAL
Intervention: Topical 0.05% tretinoin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo base cream
Number of subjects: 18
Study: 504666

Group type: EXPERIMENTAL
Intervention: 10 mg/50 ml of Xylocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg/50 ml of Xylocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain contrast medium
Number of subjects: 0
Study: 31424303

Group type: EXPERIMENTAL
Intervention: Noncontrast axial 3D T1-weighted imaging
Number of subjects: 12

Group type: COMPARATOR
Intervention: Contrast-enhanced axial 3D T1-weighted imaging
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of noncontrast to contrast-enhanced imaging
Number of subjects: 12
Study: 28782918

Group type: EXPERIMENTAL
Intervention: Self-Regulation with Large Changes
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Self-Regulation with Small Changes
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Weight Change
Number of subjects: 599
Study: 25388480

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training after training phase
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training basic phase
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training after-training phase
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training eyes-closed phase
Number of subjects: 102
Study: 23437789

Group type: EXPERIMENTAL
Intervention: 200 mg/day of red grape seed extract (RGSE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19909499

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (one gram twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16739840

Group type: EXPERIMENTAL
Intervention: Needle-knife therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 100
Study: 14644401

Group type: EXPERIMENTAL
Intervention: Insulin resistant subjects (IR)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Insulin sensitive subjects (Control)
Number of subjects: 91
Study: 10711490

Group type: EXPERIMENTAL
Intervention: Two-thumb method
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Two-finger method
Number of subjects: 209
Study: 8647966

Group type: EXPERIMENTAL
Intervention: Psychologic intervention (seven individual psychotherapy sessions over 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no psychologic intervention)
Number of subjects: 51
Study: 1524160

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrobulbar Anesthesia (RB)
Number of subjects: 40
Study: 6654626

Group type: EXPERIMENTAL
Intervention: Antacids plus vitamin A (3 X 50,000 U orally)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antacids plus vitamin A plus cyproheptadine (3 X 4 mg orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antacids only
Number of subjects: 60
Study: 3511867

Group type: EXPERIMENTAL
Intervention: Computerized axial tomography (CAT) scans
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Biochemical liver function tests (alkaline phosphatase, lactic dehydrogenase, carcinoembryonic antigen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of CAT scans and biochemical tests
Number of subjects: 100
Study: 29467022

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0
Study: 27450776

Group type: EXPERIMENTAL
Intervention: Positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 1460
Study: 24925372

Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoxaparin subcutaneously once daily
Number of subjects: 266

Group type: COMPARATOR
Intervention: 40 mg enoxaparin subcutaneously once daily
Number of subjects: 266
Study: 22414236

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral prevention program
Number of subjects: 173

Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 173
Study: 19449224

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) nasal spray, 200 microg for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100